The clinical development accelerator program

ALSA Ventures has partnered with ICON Clinical Research to accelerate clinical development of novel compounds. Eclipse maximises the benefits available to ALSA portfolio companies by drawing on the expertise of its founding partners.

Eclipse seeks exciting preclinical biotech companies developing novel therapeutics across all modalities and therapeutic areas.

The selection process is competitive, with up to four awards to be made annually.  Selected companies will be offered an equity investment of up to $5 million from ALSA Ventures.  Together with our partner ICON, we will work with selected companies on:

For further enquiries please email us at:

How does the Eclipse model work

Latest news

View ALL News

Our partners

ALSA Ventures